Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy
Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and/or pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is suppo
| Condition(s) | Asthma, Rhinitis, Allergic |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and/or pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is supported by large systematic reviews and is recommended as a cornerstone treatment option in allergic disease. Molecular based allergy diagnosis has greatly evolved and the knowledge of molecular allergen sensitization pattern has been used to better define the allergen extract composition of AIT. However, uncertainty remains if this strategy is related to an increase of efficacy. Regulation of allergen extracts for allergen immunotherapy are currently underway in Europe, but the |
| Who can participate | Inclusion Criteria: * Individuals with medical indication for aeroallergen immunotherapy(AIT) for allergic rhinoconjunctivitis or asthma, accordingly to the AIT guidelines; * Over 5 years of age; * Evidence of IgE-sensitization (positive skin prick tests and / or serum specific-IgE) * Patients have indication to AIT to house dust mites and/or grass pollen, association with other allergens is not an exclusion criteria Exclusion Criteria: * Previously performed allergen immunotherapy * Need the use of molecular allergen diagnosis to decide treatment and diagnostic strategy |
| Ages | 5 Years |
| Sex | All |
| Lead sponsor | Universidade do Porto |
| Locations | Porto, Portugal |
| Start date | 2022-07-30 |
| NCT ID | NCT05448066 |
| Official listing | https://clinicaltrials.gov/study/NCT05448066 |